Cancer Immunotherapeutics Meeting

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.12, 2004-12, pp. : 1645-1650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy

Current Pharmaceutical Design, Vol. 15, Iss. 23, 2009-08 ,pp. : 2693-2699

Bentham Science Publishers

Access to resources Recommend Favorite

Immunotherapeutics for nosocomial infections

By Patti Joseph M

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 6, 2004-06 ,pp. : 673-679

Informa Healthcare

Access to resources Recommend Favorite

Toll-Like Receptors, Cytokines and the Immunotherapeutics of Asthma

Current Pharmaceutical Design, Vol. 12, Iss. 19, 2006-07 ,pp. : 2365-2374

Bentham Science Publishers

Access to resources Recommend Favorite

Rotavirus Vaccine AVANT Immunotherapeutics/GlaxoSmithKline: 89-12, RIX4414

By Adis International Limited

Drugs in R&D, Vol. 5, Iss. 2, 2004-01 ,pp. : 113-115

Adis International

Access to resources Recommend Favorite

Strategies to Develop Allergy Immunotherapeutics with Applications of Directed Molecular Evolution

Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, Vol. 2, Iss. 3, 2003-09 ,pp. : 228-236

Bentham Science Publishers

Access to resources Recommend Favorite